Sudeep Pharma Ltd. (SUDEEPPHRM): Sudeep Pharma 52 Week High Streak: Second Straight Session
- September 2, 2026
- Posted by: Harsh Piplani
- Category: News
Sudeep Pharma 52 Week High Streak has extended into a second straight session, with the stock setting a fresh 52-week high again and posting a 4.99% cumulative move across the streak. The latest high stood at Rs 1,272.85, while the share price was last traded at Rs 1,270.70. The supplied data confirms the repeated-high pattern, but it does not establish a company-specific catalyst for the continued move.
As of 02 September 2026 at 10:18 AM IST, the stock had opened at Rs 1,259.95, touched a low of Rs 1,222.20, and moved with a turnover of Rs 0.56 crore. Its market capitalisation stood at Rs 13,670.74 crore. For readers tracking Sudeep Pharma share price action, the key point is the repeated one-year-high pattern across sessions rather than a single-day breakout alone.
Sudeep Pharma 52 Week High Streak: Consecutive High Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 1,270.7 |
| Previous Close | Rs 1,223.7 |
| Today's Move | +Rs 47 (+3.84%) |
| Open | Rs 1,259.95 |
| High | Rs 1,272.85 |
| Low | Rs 1,222.2 |
| Turnover | Rs 0.56 crore |
| Market Capitalisation | Rs 13,670.74 crore |
Sudeep Pharma Ltd. (SUDEEPPHRM) traded at Rs 1,270.7 versus the previous close of Rs 1,223.7, a rise of 3.84%. The stock opened at Rs 1,259.95, reached a high of Rs 1,272.85 and touched a low of Rs 1,222.2.
During the current session, Sudeep Pharma share price traded at Rs 1,270.70, up Rs 47 or 3.84% from the previous close of Rs 1,223.70. The stock opened at Rs 1,259.95 and moved between Rs 1,222.20 and Rs 1,272.85, which also marked the fresh 52-week high. That places the current trade very near the day’s top, without needing any additional interpretation beyond the numbers supplied.
Turnover for the session was Rs 0.56 crore, and market capitalisation was Rs 13,670.74 crore. For a reader following Sudeep Pharma share price today, the important distinction is that this is not only a one-day move: it sits inside a 52 Week High Streak that has now repeated across two sessions. The published streak article therefore focuses on the pattern across days, while the day-specific figures show how the stock is trading around that new one-year peak.
What the Repeated 52-Week Highs Show
The repeated fresh highs indicate that Sudeep Pharma 52 Week High Streak is being built one session at a time, with the stock now recording a new one-year peak on each of the last two trading days. Across that stretch, the cumulative move is 4.99%, which is the clearest streak-wide measure supplied in the data. The current high of Rs 1,272.85 is also the latest reference point for the pattern.
What the repeated 52-week highs show is limited to price behaviour in the supplied data. It does not, by itself, identify a company event, earnings trigger or sector headline. For investors searching for Sudeep Pharma New One Year High or Sudeep Pharma Back to Back 52 Week Highs, the useful takeaway is that the stock has remained above its prior one-year ceiling and has done so again on the next session. That makes the streak itself the story, not a one-off move.
Sudeep Pharma Ltd. (SUDEEPPHRM) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 13,670.74 crore |
| P/E Ratio | 75.68x |
| P/B Ratio | 14.96x |
| ROE | 25.37% |
| ROCE | 28.5% |
| EPS | Rs 16.17 |
| Book Value Per Share | Rs 81.8 |
| Dividend Yield | 0.12% |
Sudeep Pharma Ltd. (SUDEEPPHRM) fundamental metrics show P/E 75.68x, P/B 14.96x, ROE 25.37%, ROCE 28.5%. These figures provide context only and are not a buy or sell signal.
Sudeep Pharma Ltd. has a market capitalisation of Rs 13670.74 crore, which gives readers a sense of company size before judging valuation. On valuation, P/E at 75.68x, P/B at 14.96x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 25.37% and ROCE of 28.5%, helping investors compare shareholder returns and capital efficiency. Additional supplied metrics include EPS of Rs 16.17, book value per share of Rs 81.8, dividend yield of 0.12%, adding context to earnings, balance-sheet value and historical payout. Against the supplied same industry benchmark, these figures can be compared with benchmark median P/E of 31.13x, median ROE of 11.78%, median ROCE of 13.61%. These numbers explain the fundamental backdrop without converting the article into a buy or sell view.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Industry | Pharmaceuticals & Drugs |
| Benchmark Scope | same industry |
| Company P/E Ratio | 75.68x |
| Benchmark Median P/E | 31.13x |
| Benchmark Average P/E | 47.95x |
| Benchmark P/E Range | 3.68x to 653.31x |
| Company P/B Ratio | 14.96x |
| Benchmark Median P/B | 2.87x |
| Company ROE | 25.37% |
| Benchmark Median ROE | 11.78% |
| Company ROCE | 28.5% |
| Benchmark Median ROCE | 13.61% |
| Company Market Capitalisation | Rs 13,670.74 crore |
| Benchmark Median Market Cap | Rs 698.8 crore |
Sudeep Pharma Ltd. (SUDEEPPHRM) is classified under sector: Healthcare and industry: Pharmaceuticals & Drugs.
Sudeep Pharma Ltd. (SUDEEPPHRM) has a P/E ratio of 75.68x, which is above the benchmark median of 31.13x, a difference of +143.11%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.
Sudeep Pharma Ltd. (SUDEEPPHRM) has a ROE of 25.37%, which is above the benchmark median of 11.78%, a difference of +115.37%. Sudeep Pharma Ltd. (SUDEEPPHRM) has a ROCE of 28.5%, which is above the benchmark median of 13.61%, a difference of +109.4%.
Track stocks reaching yearly peaks through the Univest 52-week-high screener. The peer table below provides the company-level comparison.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Jubilant Pharmova Ltd. | JUBLPHARMA | 14,055.76 | 41.1 | 2.03 | 5.97 | 8.69 |
| Marksans Pharma Ltd. | MARKSANS | 14,634.92 | 28.28 | 4.6 | 15.31 | 21.1 |
| CORONA Remedies Ltd. | CORONA | 12,525.89 | 62.74 | 15.47 | 27.36 | 31.74 |
| Natco Pharma Ltd. | NATCOPHARM | 15,085.53 | 13.29 | 1.63 | 27.98 | 32.85 |
| Concord Biotech Ltd. | CONCORDBIO | 15,167.26 | 56.35 | 7.48 | 13.54 | 18.04 |
Sudeep Pharma Ltd. (SUDEEPPHRM) has a P/E ratio of 75.68x compared with the displayed peer median of 41.1x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 25.37% compares with a peer median of 15.31% across the companies shown in the table. ROCE stood at 28.5% versus the displayed peer median of 21.1%, providing a capital-efficiency comparison. Sudeep Pharma Ltd. (SUDEEPPHRM) has a market capitalisation of Rs 13,670.74 crore. Among the 5 peers shown, 4 have a larger market capitalisation.
Why Investors Are Watching Sudeep Pharma
- The stock has set a fresh 52-week high for a second straight session.
- The streak-wide cumulative move supplied in the data is 4.99%.
- The latest one-year high is Rs 1,272.85, which is the current reference point for the run.
- The company trades with strong return ratios in the supplied healthcare benchmark, including ROE and ROCE above sector medians.
- Its valuation remains elevated versus the supplied peer and sector set, which keeps Sudeep Pharma Stock News relevant for valuation-focused readers.
About Sudeep Pharma Ltd.
Sudeep Pharma Ltd. is part of the Pharmaceuticals & Drugs industry in the Healthcare sector. In the supplied data, the company has a market capitalisation of Rs 13,670.74 crore, a P/E of 75.68, a P/B of 14.96, ROE of 25.37%, and ROCE of 28.5%. These numbers give a compact picture of the company’s current market positioning.
For readers following Sudeep Pharma share price updates on NSE and BSE, the key facts are the repeated 52-week highs and the premium valuation. The company also shows an EPS of Rs 16.17, book value of Rs 81.8, and dividend yield of 0.12%. Those figures help place the stock within its industry and broader market context.
Track Sudeep Pharma on Univest
If you are tracking Sudeep Pharma 52 Week High Streak, the Univest stock page can help you follow the share price, market cap, valuation metrics and related company news in one place. That is useful when the stock is appearing in the “Stocks Hitting 52 Week Highs” conversation and you want a factual update rather than a single-session snapshot.
For ongoing monitoring, keep an eye on the next session’s trade around the latest one-year high, along with any fresh company filings or sector updates that may appear in the market. The current data confirms the streak pattern, but the reason for the move must come from later disclosed information if it emerges.
Disclaimer: This article is for informational purposes only and is based solely on the supplied data. It is not investment advice, a recommendation, or a forecast. Market prices can change during the session, and readers should verify live data before taking any decision.
Frequently Asked Questions
How many sessions has Sudeep Pharma now set a fresh 52-week high?
Ans. Sudeep Pharma has set a fresh 52-week high for a second straight session. The supplied data confirms the repeated pattern across two trading days, with the latest high at Rs 1,272.85.
What is the cumulative move across the Sudeep Pharma 52 Week High Streak?
Ans. The cumulative streak move supplied in the data is 4.99%. That figure is the best way to read the full two-session move rather than focusing only on the latest intraday change.
What was Sudeep Pharma trading at during the update?
Ans. As of 02 September 2026 at 10:18 AM IST, Sudeep Pharma was last traded at Rs 1,270.70, up Rs 47 or 3.84% from the previous close of Rs 1,223.70.
What does the repeated 52-week high pattern suggest?
Ans. It confirms that the stock has kept making new one-year highs across consecutive sessions. The supplied data does not establish a company-specific catalyst, so the pattern should be read as a factual price streak only.
Is Sudeep Pharma expensive on the supplied valuation metrics?
Ans. Relative to the supplied healthcare benchmark, Sudeep Pharma trades at a premium. Its P/E of 75.68 and P/B of 14.96 are both above the sector medians in the dataset.
How does Sudeep Pharma compare with its peers?
Ans. Among the supplied peers, Sudeep Pharma’s valuation is richer than most names in the list, while its ROE and ROCE compare well on the return side. That combination makes the peer comparison important for context.
What should investors watch next?
Ans. Investors can watch whether the stock continues to trade near the latest 52-week high, and whether any new company disclosure or sector update appears. The current data confirms the streak, but not the cause of it.
Track Sudeep Pharma Ltd. (SUDEEPPHRM) Share Price on Univest
Use Sudeep Pharma Ltd. (SUDEEPPHRM) live share-price page, Univest 52-week-high screener, Univest market blogs to review live stock data, yearly-high lists and related market analysis.
